| Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. | |
| | |
MedLine Citation:
|
PMID: 20580035 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Statin treatment and exercise training can reduce markers of inflammation when administered separately. The purpose of this study was to determine the effect of rosuvastatin treatment and the addition of exercise training on circulating markers of inflammation including C-reactive protein (CRP), monocyte toll-like receptor 4 (TLR4) expression, and CD14+CD16+ monocyte population size. Thirty-three hypercholesterolemic and physically inactive subjects were randomly assigned to rosuvastatin (R) or rosuvastatin/exercise (RE) groups. A third group of physically active hypercholesterolemic subjects served as a control (AC). The R and RE groups received rosuvastatin treatment (10 mg/d) for 20 weeks. From week 10 to week 20, the RE group also participated in an exercise training program (3d/wk). Measurements were made at baseline (Pre), week 10 (Mid), and week 20 (Post), and included TLR4 expression on CD14+ monocytes and CD14+CD16+ monocyte population size as determined by 3-color flow cytometry. Serum CRP was quantified by enzyme-linked immunosorbent assay. TLR4 expression on CD14+ monocytes was higher in the R group at week 20. When treatment groups (R and RE) were combined, serum CRP was lower across time. Furthermore, serum CRP and inflammatory monocyte population size were lower in the RE group compared with the R group at the Post time point. When all groups (R, RE, and AC) were combined, TLR4 expression was greater on inflammatory monocytes (CD14+CD16+) compared with classic monocytes (CD14+CD16⁻) at all time points. In conclusion, rosuvastatin may influence monocyte inflammatory response by increasing TLR4 expression on circulating monocytes. The addition of exercise training to rosuvastatin treatment further lowered CRP and reduced the size of the inflammatory monocyte population, suggesting an additive anti-inflammatory effect of exercise. |
| | |
Authors:
|
Paul M Coen; Michael G Flynn; Melissa M Markofski; Brandt D Pence; Robert E Hannemann |
Related Documents
:
|
1470015 - Anaerobic exercise causes transient changes in leukocyte subsets and il-2r expression. 22468755 - Effects of hyperoxia during recovery from 5×30-s bouts of maximal-intensity exercise. 12611775 - Exercise-induced changes to in vitro t-lymphocyte mitogen responses using cfse. 9177585 - Exercise, immunity and aging. 15515965 - The gonyautoxin 2/3 epimers reduces anal tone when injected in the anal sphincter of he... 10874255 - Improvement of exercise capacity and left ventricular diastolic function with metoprolo... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-06-26 |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 59 ISSN: 1532-8600 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2010-12-23 Revised Date: 2011-01-25 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: United States |
Other Details:
|
Languages: eng Pagination: 1775-83 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Wastl Human Performance Laboratory, Purdue University, West Lafayette, IN, USA. pmc17@pitt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antigens, CD14 / metabolism* C-Reactive Protein / metabolism* Exercise* Fluorobenzenes / therapeutic use* GPI-Linked Proteins / metabolism Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Longitudinal Studies Middle Aged Monocytes / metabolism* Pyrimidines / therapeutic use* Receptors, IgG / metabolism* Sulfonamides / therapeutic use* Toll-Like Receptor 4 / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD14; 0/FCGR3B protein, human; 0/Fluorobenzenes; 0/GPI-Linked Proteins; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Receptors, IgG; 0/Sulfonamides; 0/Toll-Like Receptor 4; 287714-41-4/rosuvastatin; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Epigallocatechin gallate-mediated protection against tumor necrosis factor-alpha-induced monocyte ch...
Next Document: Systemic hemodynamics in relation to glucose tolerance: the Health 2000 Survey.